elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q26769884-2D125178-951C-49D6-B1F9-D33D59D075E3
Q26769884-2D125178-951C-49D6-B1F9-D33D59D075E3
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26769884-2D125178-951C-49D6-B1F9-D33D59D075E3
Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential
P2860
Q26769884-2D125178-951C-49D6-B1F9-D33D59D075E3
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26769884-2D125178-951C-49D6-B1F9-D33D59D075E3
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
da8fe9ffe9e9f074810f60d20acb0d9a9f1f3f82
P2860
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase